explore -WSS

explore

author：focus 2025-09-29 01:35:58 - browse：5282

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

hotspot

WSS

WHO may add ‘noma' to its list of neglected tropical diseases

Generative AI mines health records to identify patients’ social needs

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Readout Newsletter: What happened with Sarepta's Duchenne data

Eli Lilly to pay $200M for Beam’s stake in gene

leisure time

explore

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Dobbs anniversary: the lost opportunity of abortion as health care

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Wildfire smoke exposes gaps in outdoor worker protections

Meta's Zuckerberg and Chan on track to put $50 billion into science

What does generative AI mean for health care? We asked experts

Emergency medicine has repudiated 'excited delirium.' Now what?

Virginia high school admissions case could be legal follow

Designating disabled people as health disparity population is crucial

knowledge

Readout Newsletter: XBI biotech index, Akero Therapeutics

Meta's Zuckerberg and Chan on track to put $50 billion into science

The SUPPORT Act is critical to fighting the opioid crisis

JPM 2024: Nvidia claims we're in biological revolution. Are we?

The FDA weighs the risks of candy

Medtronic CEO on promising devices for diabetes, hypertension

Wikipedia

hotspot

Wikipedia

leisure time